Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares for approximately $5.5 million at an average price of $576.47, reducing her direct ownership by 2.84% to 324,443 shares.
- United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, though revenue of $783.3 million missed expectations and declined 1.9% year over year.
- A federal court ruled that Liquidia’s Yutrepia infringes two United Therapeutics patents, potentially strengthening Tyvaso’s market protection, although appeals and regulatory delays remain risks. Analysts maintain a “Moderate Buy” consensus with an average price target of $621.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $576.47, for a total value of $5,476,465.00. Following the completion of the transaction, the chief executive officer directly owned 324,443 shares of the company's stock, valued at approximately $187,031,656.21. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
United Therapeutics Trading Down 5.2%
Shares of United Therapeutics stock opened at $541.70 on Friday. The business's fifty day simple moving average is $510.30 and its 200 day simple moving average is $539.65. The firm has a market capitalization of $23.23 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 2.86 and a beta of 0.49. United Therapeutics Corporation has a 12 month low of $409.07 and a 12 month high of $609.35.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business's revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.41 earnings per share. Analysts predict that United Therapeutics Corporation will post 26.21 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Toth Financial Advisory Corp increased its stake in shares of United Therapeutics by 2,400.0% in the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $30,000. Caitlin John LLC bought a new position in United Therapeutics in the 2nd quarter worth approximately $37,000. International Assets Investment Management LLC boosted its holdings in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company's stock worth $45,000 after buying an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. purchased a new position in United Therapeutics in the 2nd quarter valued at approximately $81,000. Hedge funds and other institutional investors own 94.08% of the company's stock.
Analyst Ratings Changes
A number of brokerages recently weighed in on UTHR. Cantor Fitzgerald reissued an "overweight" rating on shares of United Therapeutics in a report on Thursday. Weiss Ratings downgraded shares of United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Royal Bank Of Canada lowered their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Bank of America dropped their target price on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Finally, The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a research report on Thursday, September 24th. They set a "sell" rating and a $321.00 target price for the company. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $621.00.
Read Our Latest Stock Analysis on UTHR
United Therapeutics News Roundup
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: A Delaware federal court ruled that Liquidia’s Yutrepia infringes two United Therapeutics patents covering inhaled treprostinil for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The court also rejected Liquidia’s arguments that the patents were invalid, strengthening the competitive position of United Therapeutics’ Tyvaso franchise. United Therapeutics prevails in patent litigation
- Positive Sentiment: The decision could limit Yutrepia’s use in the PH-ILD market and may support United Therapeutics’ request for FDA action requiring labeling that excludes the disputed indication. Investors view the ruling as potentially extending Tyvaso’s market protection and supporting future cash flow. UTHR prevails in Yutrepia patent dispute
- Neutral Sentiment: The ruling may still face appeals, additional legal proceedings, or regulatory delays, so the timing and ultimate commercial benefit remain uncertain. Analyst opinions are mixed, with some bullish targets but at least one notably bearish view, creating potential volatility. Analysts have conflicting sentiments on healthcare companies
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for approximately $5.5 million on October 1, following another 9,500 shares sold over the prior two days. EVP Paul Mahon also sold 8,300 shares for approximately $4.7 million. The transactions may reflect scheduled selling, but the concentration of insider sales can weigh on sentiment after the stock’s sharp advance. United Therapeutics insider selling
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company's products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.
United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
